Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2024—Abbott’s i-Stat TBI cartridge has received FDA clearance for use with whole blood, allowing clinicians to help assess patients with suspected concussion at the patient’s bedside. The test measures ubiquitin C-terminal hydrolase L1 and glial fibrillary acidic protein to help evaluate patients 18 years of age and older up to 24 hours after injury. Results are available in 15 minutes on the portable i-Stat Alinity system.
May 2024—Pillar Biosciences announced that the FDA has approved the company’s premarket approval supplement application for its OncoReveal CDx pan-cancer solid tumor in vitro diagnostic assay. The panel covers 22 clinically relevant genes in one multiplex reaction and has a fully automatable workflow with a sample-to-report time of as little as 48 hours. Up to 46 clinical samples can be batched on a single MiSeq Dx run.
May 2024—Bio-Rad Laboratories has launched its Unity Next Peer QC data management software in Europe, the Middle East, and Africa. The software is designed to help troubleshoot quality control failures and increase confidence in patient testing results and offers on-demand access to peer reporting and quality control data. Labs new to Bio-Rad’s suite of QC data management products can get guided support and training from the company.
May 2024—Sysmex America announced it will sell hemostasis instruments and reagents to laboratories in the United States under the company’s mutual original equipment manufacturer agreement with Siemens Healthineers. The agreement allows the companies to distribute hemostasis instruments provided by Sysmex and reagents provided by Siemens under their respective brands.
May 2024—Scopio Labs announced it has been granted de novo clearance by the FDA for its Full-Field Bone Marrow Aspirate application for use on the company’s X100 and X100HT platforms. The application is designed to assist users in streamlining bone marrow aspirate review and reporting. It automates the detection and visualization of hematopoietic cells in stained smears, facilitating evaluations such as bone marrow smear quality assessment, blast cell and plasma cell estimation, and calculation of the myeloid to erythroid ratio.
May 2025—NanoString Technologies announced that substantially all of its assets will be acquired by Bruker Corp. for approximately $392.6 million in cash consideration, plus the assumption of certain liabilities. The transaction was agreed to under a court-supervised Chapter 11 sale process and is expected to close in early May.
May 2024—Verichem Laboratories has upgraded its Web-based, CLIA-compliant data reduction and test reporting software. The new version allows customers to save reports on the company’s server for future editing and edit previous submissions for up to three days after the initial submission. Previous submissions are autosaved so users can edit data without rekeying or reentering any other component information. The software is available to customers at no cost.
May 2024—Newcomer Supply announced it is distributing HistoCyte Laboratories cell line controls for research use only. HistoCyte uses proprietary methods to process cell lines into tissue-like controls. The products are standardized, developed, and manufactured to provide consistent morphology and staining results throughout the FFPE block. Cell line controls are available as either precut slides or in cell microarray blocks.
May 13, 2024—Qiagen announced that the FDA has cleared its QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use.
May 8, 2024—Indica Labs received FDA 510(k) clearance for its Halo AP Dx digital pathology platform for use in primary diagnosis.
